DiObex, Inc. Begins Treating Patients with Type 2 Diabetes in Randomized Clinical Trial

DiObex, Inc. has announced the initiation of a clinical trial to evaluate the safety and pharmacokinetics of DIO-902, a cortisol synthesis inhibitor, in patients with type 2 diabetes. The 2-week trial will assess the effects of three different dose levels of DIO-902 on glucose levels, blood pressure, and cholesterol. According to the company, preclinical studies have shown that DIO-902 is a more effective and safer alternative to the racemate of ketoconazole, which has been used to treat type 2 diabetes. The development of a drug that can manage multiple risk factors simultaneously would be a significant breakthrough in the treatment of type 2 diabetes, with significant implications for patient care and outcomes.

Key Takeaways:

DiObex, Inc. has initiated a randomized, placebo-controlled clinical trial to evaluate the safety and pharmacokinetics of DIO-902, a cortisol synthesis inhibitor, in patients with type 2 diabetes.
The 2-week trial will assess the effects of three different dose levels of DIO-902 on glucose levels, blood pressure, and cholesterol.
Preclinical studies have shown that DIO-902 is a more effective and safer alternative to the racemate of ketoconazole, which has been used to treat type 2 diabetes.
The development of a drug that can manage multiple risk factors simultaneously would be a significant breakthrough in the treatment of type 2 diabetes, with significant implications for patient care and outcomes.
Daniel Green, President of DiObex, commented on the company's excitement about the clinical development of DIO-902, citing the target's popularity among big pharma companies.
DIO-902 has been shown to be responsible for virtually all of the cortisol synthesis inhibitory activity present in the racemate of ketoconazole.
Dr. Timothy Stewart, Vice President of Research at DiObex, highlighted the substantial clinical benefits of inhibiting cortisol synthesis, including improved glucose control and lowered blood pressure and cholesterol.
Dr. Bernice Welles, Vice President of Development at DiObex, noted that a drug that can manage multiple risk factors simultaneously would be a significant advance in the treatment of type 2 diabetes.

Statistics:

The clinical trial will involve 2 weeks of treatment with DIO-902.
Preclinical studies have shown that DIO-902 is more effective and safer than the racemate of ketoconazole.
3 dose levels of DIO-902 will be assessed in the clinical trial.

Sources:

DiObex, Inc.
Daniel Green, President of DiObex
Dr. Timothy Stewart, Vice President of Research at DiObex
Dr. Bernice Welles, Vice President of Development at DiObex
Health & Medicine Week editors
NewsRx.com